Literature DB >> 12359124

Structural basis of Fabry disease.

Scott C Garman1, David N Garboczi.   

Abstract

Fabry disease is a lysosomal storage disease caused by deficiency in the enzyme alpha-galactosidase (alpha-GAL). To understand the molecular defects responsible for Fabry disease, we have collected more than 190 reported point and stop mutations and mapped them onto a model of human alpha-GAL based on the X-ray structure of the closely related enzyme alpha-N-acetylgalactosaminidase (alpha-NAGAL). The locations of the human alpha-GAL point mutations reveal two major classes of Fabry disease protein defects: active site mutations and folding mutations. Active site mutations reduce enzymatic activity by perturbing the active site without necessarily affecting the overall alpha-GAL structure. Folding mutations reduce the stability of alpha-GAL by disrupting its hydrophobic core. Examining the frequency of mutation around each alpha-GAL residue identifies the active site as a hotspot for mutations leading to Fabry disease. This study furthers our understanding of the structural basis for mutations leading to Fabry disease, from which new avenues for the treatment of lysosomal storage diseases may be developed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359124     DOI: 10.1016/s1096-7192(02)00151-8

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  15 in total

1.  α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.

Authors:  Aleksandra Siekierska; Greet De Baets; Joke Reumers; Rodrigo Gallardo; Stanislav Rudyak; Kerensa Broersen; Jose Couceiro; Joost Van Durme; Joost Schymkowitz; Frederic Rousseau
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

2.  Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.

Authors:  Sang H Shin; Stefanie Kluepfel-Stahl; Adele M Cooney; Christine R Kaneski; Jane M Quirk; Raphael Schiffmann; Roscoe O Brady; Gary J Murray
Journal:  Pharmacogenet Genomics       Date:  2008-09       Impact factor: 2.089

3.  Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.

Authors:  Robert Dobrovolny; Lenka Dvorakova; Jana Ledvinova; Sudheera Magage; Jan Bultas; Jean C Lubanda; Milan Elleder; Debora Karetova; Marketa Pavlikova; Martin Hrebicek
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

4.  The molecular basis of pharmacological chaperoning in human α-galactosidase.

Authors:  Abigail I Guce; Nathaniel E Clark; Jerome J Rogich; Scott C Garman
Journal:  Chem Biol       Date:  2011-12-23

Review 5.  Infrared imaging microscopy of bone: illustrations from a mouse model of Fabry disease.

Authors:  Adele L Boskey; Michel Goldberg; Ashok Kulkarni; Santiago Gomez
Journal:  Biochim Biophys Acta       Date:  2006-03-15

6.  Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.

Authors:  Jung Young Park; Gu Hwan Kim; Sung Su Kim; Jung Min Ko; Jin Joo Lee; Han Wook Yoo
Journal:  Exp Mol Med       Date:  2009-01-31       Impact factor: 8.718

7.  Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.

Authors:  Jinhai Wang; Jay Lozier; Gibbes Johnson; Susan Kirshner; Daniela Verthelyi; Anne Pariser; Elizabeth Shores; Amy Rosenberg
Journal:  Nat Biotechnol       Date:  2008-08       Impact factor: 54.908

8.  Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.

Authors:  Satoshi Ishii; Hui-Hwa Chang; Kunito Kawasaki; Kayo Yasuda; Hui-Li Wu; Scott C Garman; Jian-Qiang Fan
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

9.  A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.

Authors:  Xiaoyang Wu; Evan Katz; Maria Cecilia Della Valle; Kirsten Mascioli; John J Flanagan; Jeffrey P Castelli; Raphael Schiffmann; Pol Boudes; David J Lockhart; Kenneth J Valenzano; Elfrida R Benjamin
Journal:  Hum Mutat       Date:  2011-07-12       Impact factor: 4.878

Review 10.  Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease.

Authors:  Yuan Wu; Hong Xia; Jinzhong Yuan; Hongbo Xu; Xiong Deng; Jun Liu; Hao Zhang; Hao Deng
Journal:  Curr Genomics       Date:  2018-01       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.